1 Study Coverage
1.1 Hereditary Cancer Testing Revenue in Hereditary Cancer Testing Business (2017-2022) & (US$ Million) Introduction
1.2 Global Hereditary Cancer Testing Outlook 2017 VS 2022 VS 2028
1.2.1 Global Hereditary Cancer Testing Market Size for the Year 2017-2028
1.2.2 Global Hereditary Cancer Testing Market Size for the Year 2017-2028
1.3 Hereditary Cancer Testing Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Hereditary Cancer Testing in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Hereditary Cancer Testing Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Hereditary Cancer Testing Market Dynamics
1.4.1 Hereditary Cancer Testing Industry Trends
1.4.2 Hereditary Cancer Testing Market Drivers
1.4.3 Hereditary Cancer Testing Market Challenges
1.4.4 Hereditary Cancer Testing Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Hereditary Cancer Testing by Type
2.1 Hereditary Cancer Testing Market Segment by Type
2.1.1 RNA Testing
2.1.2 DNA Testing
2.2 Global Hereditary Cancer Testing Market Size by Type (2017, 2022 & 2028)
2.3 Global Hereditary Cancer Testing Market Size by Type (2017-2028)
2.4 United States Hereditary Cancer Testing Market Size by Type (2017, 2022 & 2028)
2.5 United States Hereditary Cancer Testing Market Size by Type (2017-2028)
3 Hereditary Cancer Testing by Application
3.1 Hereditary Cancer Testing Market Segment by Application
3.1.1 Breast Cancer
3.1.2 Gastrointestinal Cancer
3.1.3 Prostate Cancer
3.1.4 Respiratory/Lung Cancer
3.1.5 Other Cancers
3.2 Global Hereditary Cancer Testing Market Size by Application (2017, 2022 & 2028)
3.3 Global Hereditary Cancer Testing Market Size by Application (2017-2028)
3.4 United States Hereditary Cancer Testing Market Size by Application (2017, 2022 & 2028)
3.5 United States Hereditary Cancer Testing Market Size by Application (2017-2028)
4 Global Hereditary Cancer Testing Competitor Landscape by Company
4.1 Global Hereditary Cancer Testing Market Size by Company
4.1.1 Top Global Hereditary Cancer Testing Companies Ranked by Revenue (2021)
4.1.2 Global Hereditary Cancer Testing Revenue by Player (2017-2022)
4.2 Global Hereditary Cancer Testing Concentration Ratio (CR)
4.2.1 Hereditary Cancer Testing Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Hereditary Cancer Testing in 2021
4.2.3 Global Hereditary Cancer Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Hereditary Cancer Testing Headquarters, Revenue in Hereditary Cancer Testing Business (2017-2022) & (US$ Million) Type
4.3.1 Global Hereditary Cancer Testing Headquarters and Area Served
4.3.2 Global Hereditary Cancer Testing Companies Revenue in Hereditary Cancer Testing Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Hereditary Cancer Testing Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Hereditary Cancer Testing Market Size by Company
4.5.1 Top Hereditary Cancer Testing Players in United States, Ranked by Revenue (2021)
4.5.2 United States Hereditary Cancer Testing Revenue by Players (2020, 2021 & 2022)
5 Global Hereditary Cancer Testing Market Size by Region
5.1 Global Hereditary Cancer Testing Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Hereditary Cancer Testing Market Size by Region (2017-2028)
5.2.1 Global Hereditary Cancer Testing Market Size by Region: 2017-2022
5.2.2 Global Hereditary Cancer Testing Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Hereditary Cancer Testing Market Size YoY Growth 2017-2028
6.1.2 North America Hereditary Cancer Testing Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Hereditary Cancer Testing Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Hereditary Cancer Testing Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Hereditary Cancer Testing Market Size YoY Growth 2017-2028
6.3.2 Europe Hereditary Cancer Testing Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Hereditary Cancer Testing Market Size YoY Growth 2017-2028
6.4.2 Latin America Hereditary Cancer Testing Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Hereditary Cancer Testing Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Hereditary Cancer Testing Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Ambry Genetics (Konica Minota)
7.1.1 Ambry Genetics (Konica Minota) Company Details
7.1.2 Ambry Genetics (Konica Minota) Business Overview
7.1.3 Ambry Genetics (Konica Minota) Hereditary Cancer Testing Introduction
7.1.4 Ambry Genetics (Konica Minota) Revenue in Hereditary Cancer Testing Business (2017-2022)
7.1.5 Ambry Genetics (Konica Minota) Recent Development
7.2 Asper Biogene
7.2.1 Asper Biogene Company Details
7.2.2 Asper Biogene Business Overview
7.2.3 Asper Biogene Hereditary Cancer Testing Introduction
7.2.4 Asper Biogene Revenue in Hereditary Cancer Testing Business (2017-2022)
7.2.5 Asper Biogene Recent Development
7.3 Natera
7.3.1 Natera Company Details
7.3.2 Natera Business Overview
7.3.3 Natera Hereditary Cancer Testing Introduction
7.3.4 Natera Revenue in Hereditary Cancer Testing Business (2017-2022)
7.3.5 Natera Recent Development
7.4 Caris Life Sciences
7.4.1 Caris Life Sciences Company Details
7.4.2 Caris Life Sciences Business Overview
7.4.3 Caris Life Sciences Hereditary Cancer Testing Introduction
7.4.4 Caris Life Sciences Revenue in Hereditary Cancer Testing Business (2017-2022)
7.4.5 Caris Life Sciences Recent Development
7.5 BioReference Laboratories (GeneDx)
7.5.1 BioReference Laboratories (GeneDx) Company Details
7.5.2 BioReference Laboratories (GeneDx) Business Overview
7.5.3 BioReference Laboratories (GeneDx) Hereditary Cancer Testing Introduction
7.5.4 BioReference Laboratories (GeneDx) Revenue in Hereditary Cancer Testing Business (2017-2022)
7.5.5 BioReference Laboratories (GeneDx) Recent Development
7.6 LabSolutions
7.6.1 LabSolutions Company Details
7.6.2 LabSolutions Business Overview
7.6.3 LabSolutions Hereditary Cancer Testing Introduction
7.6.4 LabSolutions Revenue in Hereditary Cancer Testing Business (2017-2022)
7.6.5 LabSolutions Recent Development
7.7 Progenity?Inc
7.7.1 Progenity?Inc Company Details
7.7.2 Progenity?Inc Business Overview
7.7.3 Progenity?Inc Hereditary Cancer Testing Introduction
7.7.4 Progenity?Inc Revenue in Hereditary Cancer Testing Business (2017-2022)
7.7.5 Progenity?Inc Recent Development
7.8 ARUP Laboratories
7.8.1 ARUP Laboratories Company Details
7.8.2 ARUP Laboratories Business Overview
7.8.3 ARUP Laboratories Hereditary Cancer Testing Introduction
7.8.4 ARUP Laboratories Revenue in Hereditary Cancer Testing Business (2017-2022)
7.8.5 ARUP Laboratories Recent Development
7.9 Myriad
7.9.1 Myriad Company Details
7.9.2 Myriad Business Overview
7.9.3 Myriad Hereditary Cancer Testing Introduction
7.9.4 Myriad Revenue in Hereditary Cancer Testing Business (2017-2022)
7.9.5 Myriad Recent Development
7.10 NeoGenomics
7.10.1 NeoGenomics Company Details
7.10.2 NeoGenomics Business Overview
7.10.3 NeoGenomics Hereditary Cancer Testing Introduction
7.10.4 NeoGenomics Revenue in Hereditary Cancer Testing Business (2017-2022)
7.10.5 NeoGenomics Recent Development
7.11 Blueprint Genetics
7.11.1 Blueprint Genetics Company Details
7.11.2 Blueprint Genetics Business Overview
7.11.3 Blueprint Genetics Hereditary Cancer Testing Introduction
7.11.4 Blueprint Genetics Revenue in Hereditary Cancer Testing Business (2017-2022)
7.11.5 Blueprint Genetics Recent Development
7.12 CellMax Life
7.12.1 CellMax Life Company Details
7.12.2 CellMax Life Business Overview
7.12.3 CellMax Life Hereditary Cancer Testing Introduction
7.12.4 CellMax Life Revenue in Hereditary Cancer Testing Business (2017-2022)
7.12.5 CellMax Life Recent Development
7.13 Fulgent Genetics
7.13.1 Fulgent Genetics Company Details
7.13.2 Fulgent Genetics Business Overview
7.13.3 Fulgent Genetics Hereditary Cancer Testing Introduction
7.13.4 Fulgent Genetics Revenue in Hereditary Cancer Testing Business (2017-2022)
7.13.5 Fulgent Genetics Recent Development
7.14 Strand Life Sciences
7.14.1 Strand Life Sciences Company Details
7.14.2 Strand Life Sciences Business Overview
7.14.3 Strand Life Sciences Hereditary Cancer Testing Introduction
7.14.4 Strand Life Sciences Revenue in Hereditary Cancer Testing Business (2017-2022)
7.14.5 Strand Life Sciences Recent Development
7.15 Myogenes
7.15.1 Myogenes Company Details
7.15.2 Myogenes Business Overview
7.15.3 Myogenes Hereditary Cancer Testing Introduction
7.15.4 Myogenes Revenue in Hereditary Cancer Testing Business (2017-2022)
7.15.5 Myogenes Recent Development
7.16 LabCorp
7.16.1 LabCorp Company Details
7.16.2 LabCorp Business Overview
7.16.3 LabCorp Hereditary Cancer Testing Introduction
7.16.4 LabCorp Revenue in Hereditary Cancer Testing Business (2017-2022)
7.16.5 LabCorp Recent Development
7.17 Quest Diagnostics
7.17.1 Quest Diagnostics Company Details
7.17.2 Quest Diagnostics Business Overview
7.17.3 Quest Diagnostics Hereditary Cancer Testing Introduction
7.17.4 Quest Diagnostics Revenue in Hereditary Cancer Testing Business (2017-2022)
7.17.5 Quest Diagnostics Recent Development
7.18 Pathway Genomics
7.18.1 Pathway Genomics Company Details
7.18.2 Pathway Genomics Business Overview
7.18.3 Pathway Genomics Hereditary Cancer Testing Introduction
7.18.4 Pathway Genomics Revenue in Hereditary Cancer Testing Business (2017-2022)
7.18.5 Pathway Genomics Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
